• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Wendy B. London, PhD

Associate Professor, Department of Pediatrics, Harvard Medical School

Director of Biostatistics, Medicine, Boston Children's Hospital

Director, Clinical Translational Investigation Program, Pedatric Hematology/Oncology, Dana-Farber Cancer Institute

Contact Info

Wendy London
Dana-Farber Cancer Institute
450 Brookline Avenue

Boston, MA, 02215
Mailstop: Dana 3
Phone: 617-632-4895
wendy.london@childrens.harvard.edu

Assistant

Ana Souza
Division of Hematology/Oncology
Boston Children's Hospital
450 Brookline Avenue, D-155E
Boston, MA, 02215
Phone: 617-632-6148
Fax: 617-582-8604
ana.souza@childrens.harvard.edu

DF/HCC Program Affiliation

Biostatistics and Computational Biology

DF/HCC Associations

Member, Center Scientific Council
Director, Survey And Data Management

Research Abstract

Dr. London has three primary research interests: neuroblastoma, prognostic stratification, and design of clinical trials. Her findings on the effect of age on neuroblastoma outcome resulted in a reduction of therapy for patients 12-18 months old. In the consensus efforts of the International Neuroblastoma Risk Group (INRG), she is the chair the Statistics Committee. Dr. London and her committee assembled the largest neuroblastoma database in the world (n=11,500). For prognostic stratification of this database, she performed survival tree regression, whereby 16 pre-treatment groups were determined, each statistically and/or clinically unique, accepted worldwide as building blocks for future trials. In this project, Dr. London eliminated the redundancy of histopathologic classification and age in risk stratification. As the Lead Statistician for the Neuroblastoma Committee of the Children’s Oncology Group, Dr. London’s collaborative neuroblastoma research includes: a) therapy reduction for low-risk and intermediate-risk neuroblastoma; b) demonstrating no role for purging in high-risk neuroblastoma; and, c) demonstrating a 20% improvement in 2-year event-free survival for high-risk neuroblastoma patients treated post-transplant with cytokines and chimeric 14.18 antibody (immunotherapy).

Dr. London has performed statistical methodological research in the design of clinical trials. She developed new methods for stratified Phase II designs, now widely used in multi-center trials for small, heterogeneous cohorts. Dr. London performed a novel application of casual inference methodology in a Phase II trial in order to improve the ability to interpret long-term outcome despite confounding by off-protocol therapy.

Publications

View All Publications